mAbs (Dec 2023)

TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life

  • Emma Davé,
  • Oliver Durrant,
  • Neha Dhami,
  • Joanne Compson,
  • Janice Broadbridge,
  • Sophie Archer,
  • Asher Maroof,
  • Kevin Whale,
  • Karelle Menochet,
  • Pierre Bonnaillie,
  • Emily Barry,
  • Gavin Wild,
  • Claude Peerboom,
  • Pallavi Bhatta,
  • Mark Ellis,
  • Matthew Hinchliffe,
  • David P. Humphreys,
  • Sam P. Heywood

DOI
https://doi.org/10.1080/19420862.2022.2160229
Journal volume & issue
Vol. 15, no. 1

Abstract

Read online

ABSTRACTTrYbe® is an Fc-free therapeutic antibody format, capable of engaging up to three targets simultaneously, with long in vivo half-life conferred by albumin binding. This format is shown by small-angle X-ray scattering to be conformationally flexible with favorable ‘reach’ properties. We demonstrate the format’s broad functionality by co-targeting of soluble and cell surface antigens. The benefit of monovalent target binding is illustrated by the lack of formation of large immune complexes when co-targeting multivalent antigens. TrYbes® are manufactured using standard mammalian cell culture and protein A affinity capture processes. TrYbes® have been formulated at high concentrations and have favorable drug-like properties, including stability, solubility, and low viscosity. The unique functionality and inherent developability of the TrYbe® makes it a promising multi-specific antibody fragment format for antibody therapy.

Keywords